Schrödinger, Inc.

NASDAQ•SDGR

CEO: Dr. Ramy Farid Ph.D.

Sector: Healthcare

Industry: Medical - Healthcare Information Services

Listing Date: 2020-02-06

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Contact Information

1540 Broadway, 24th Floor, New York, NY, 10036, United States

212-295-5800

www.schrodinger.com

Market Cap

$1.08B

P/E (TTM)

-10.3

29.2

Dividend Yield

52W High

$23.75

52W Low

$10.95

52W Range

27%

Rank46Top 59.5%

3.5

F-Score

Modified Piotroski Analysis

Based on 8-year fundamentals

Weak • 3.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2018-2025

Financial Dashboard

Q1 2026 Data

Revenue

$58.59M+0.00%

4-Quarter Trend

EPS

-$0.81+0.00%

4-Quarter Trend

FCF

-$17.34M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Increased 23% Total revenues reached $255.9 M in 2025, up 23% from $207.5 M in 2024, driven by software and collaboration growth.

Drug Discovery Revenue Surged Drug discovery revenue grew 107% to $56.4 M in 2025, primarily due to the Novartis collaboration services initiated in late 2024.

Net Loss Significantly Reduced Net loss narrowed substantially to ($103.3 M) in 2025, an $83.9 M improvement from the ($187.1 M) loss reported in 2024.

Top Pharma Cohort ACV Grows Top 20 Pharma cohort ACV increased to $80.8 M in 2025, reflecting continued scaling adoption of computational software solutions.

Risk Factors

History of Significant Operating Losses Company has history of significant operating losses; expects to incur further losses over the next several years impacting profitability goals.

Need for Additional Capital Funding Additional capital likely required to fund ongoing proprietary drug discovery programs and platform investment; failure impacts competition.

Drug Development Success Uncertain Proprietary drug candidates face high failure rates in clinical trials; success is not assured despite promising preclinical data.

Software Renewal Rates Critical Business suffers if existing customers fail to renew software licenses or renew agreements at less favorable pricing terms.

Outlook

Advance Proprietary Drug Pipeline Plan to explore strategic partnerships for SGR-1505 and SGR-3515 programs to advance development beyond current Phase 1 trials.

Predictive Toxicology Solution Launch Expect to launch predictive toxicology solution commercially and make it broadly available to customers during the 2026 calendar year.

Restructuring Yields Cost Savings May 2025 restructuring aims to reduce workforce by 7%, expecting approximately $30 M in annualized operating expense reductions.

Cash Sufficient for 24 Months Cash, equivalents, and securities of $402.3 M as of year-end 2025 provide funding runway for at least the next 24 months.

Peer Comparison

Revenue (TTM)

TDOC

$2.51B

-1.5%

GRDN

$1.46B

+13.5%

PGNY

$1.29B

+6.6%

Gross Margin (Latest Quarter)

GDRX

78.4%

-0.9pp

NVCR

77.6%

-3.9pp

TXG

70.4%

-2.8pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.75B	-21.2	-32.5%	0.7%
TXG	$3.66B	-163.3	-2.9%	8.0%
GRDN	$2.73B	51.4	27.2%	8.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

2.3%

Moderate Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Aug 5, 2026

EPS:-$0.60

Revenue:$48.08M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data